Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655064 (Buffer Solution for Injection) in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)
Latest Information Update: 11 Aug 2023
At a glance
- Drugs BI 655064 (Primary)
- Indications Idiopathic thrombocytopenic purpura; Lupus nephritis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 13 Oct 2020 Prof. In-Jin Jang is the principal investigator as per the results published in in the British Journal of Clinical Pharmacology
- 13 Oct 2020 Results published in the British Journal of Clinical Pharmacology
- 19 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.